David Baltimore is listed as a director on 26 SEC Form D filings by 4 issuers between Jul 2009 and Dec 2021: Immune Design Corp. (Seattle, WA — biotechnology — 2009–2014; $48.5M reported sold to 8 investors), Regulus Therapeutics Inc. (San Diego, CA — pharmaceuticals — 2010–2021; $34.6M reported sold to 21 investors), Nanomedix Inc. (San Diego, CA — other health care — 2013; $50K reported sold to 1 investors) and AMGEN INC (Thousand Oaks, CA — biotechnology — 2011–2015; 34 investors reported).
What this means A repeat sponsor — 4 separate companies raised money with this person listed as director, over about 12 years. Across those companies the filings report $83.1M sold in total.
Listed alongside Brian Atwood (11 shared filings), Stelios Papadopoulos (9 shared filings), Bruce Carter (8 shared filings), Ed Penhoet (7 shared filings), B. Lynne Parshall (6 shared filings) and 77 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around David. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 26 public filings for David Baltimore and found 9 differences, 4 worth asking the sponsor about: Amount sold went down between filings; Investor count went down between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.